-
With FSHD, dealing with pain is a daily challenge for me
In a daily devotional I’m reading titled “Incurable Faith: 120 Devotions of Lasting Hope for […]
-
Important Update: Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
CureDuchenne is sharing a community letter from Sarepta announcing a strategic company restructuring and pipeline […]
-
First participant dosed in novel AAV-gene therapy trial for DMD-associated cardiomyopathy
Medera, and its clinical division Sardocor, announced that the first participant was dosed with AAV1.SERCA2a […]
-
MDA Ambassador Guest Blog: The Joy of Accessible Sailing
Mike Huddleston is 62 years old. He is originally from California and now lives in […]
-
Capricor plans for deramiocel resubmission after FDA rejection
Capricor Therapeutics will resubmit its application for U.S. Food and Drug Administration (FDA) approval of […]
-
FDA indicated to Capricor that it will be unable to approve Deramiocel without additional data
Capricor Therapeutics announced that it has received a Complete Response Letter indicating that the FDA […]
-
Finding solace: Why I need July’s slower pace
July is my favorite month. Many people who know me might be surprised by that, […]
-
Capricor Therapeutics Receives Complete Response Letter Regarding Deramiocel (CAP-1002)
On July 9th, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter […]
-
Expedia’s New Initiative is Transforming Accessibility for Short-Term Rentals
Lorraine Woodward, founder and CEO of Becoming rentABLE. Expedia Group is not only opening the […]
-
Post AAV Gene Therapy Resources
As therapeutic options for Duchenne advance, we are seeing continued development of additional AAV gene […]
